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Who Should Decide? Decision-Making Preferences for Primary HPV Testing for
Cervical Cancer Screening Among U.S. Women
Abstract
Revised U.S. guidelines for cervical cancer screening provide the option of primary human papillomavirus
(HPV) testing, Pap testing, or co-testing. Primary HPV testing has not yet been an option for American
women, and women may be reluctant to change screening methods. The purpose of this study was to
assess correlates of women’s preferences for primary HPV testing decision-making (self, provider, or
shared) for cervical cancer screening. Women, aged 30-65, completed an online survey in June of 2018 (n
= 812). The outcome variable was preference for decision-making for an HPV test instead of a Pap test
on a scale of, healthcare provider, me, or shared. Predictor variables included testing attitudes, social
norms, information seeking, previous screening, and socio-demographics. Women who disagreed that
people important to them think that they should get the HPV test instead of a Pap test, who were not
willing to receive an HPV test instead of a Pap test, and who did not receive HPV vaccinations were less
likely to include a provider in their decision-making. In contrast, women who were not up-to-date with their
cervical cancer screenings, who had some college or technical level education, or who were over 50 years
of age were more likely to prefer to have a healthcare provider included in their decision-making process.
While some variation was discovered, women mostly preferred a shared decision or personal decision for
HPV testing. Resources to facilitate the decision-making process about this new option for cervical
cancer screening are needed.

Keywords
cervical cancer screening, HPV testing, decision-making, women

Acknowledgements/Disclaimers/Disclosures
We would like to acknowledge Sarah Matthes and Morgan O’Neal for their contributions to this project.
The authors have no conflict of interest to report, financial or otherwise.

Authors
Erika L. Thompson, Ashvita Garg, Katharine J. Head, Stacey B. Griner, Annalynn M. Galvin, and Tracey E.
Barnett

This research article is available in Health Behavior Research: https://newprairiepress.org/hbr/vol4/iss1/7

Thompson et al.: Decision-Making Preferences for Primary HPV Testing

Who Should Decide? Decision-making Preferences for Primary HPV Testing for Cervical
Cancer Screening Among U.S. Women
Erika L. Thompson, PhD, MPH*
Ashvita Garg, MBBS, MPH
Katharine J. Head, PhD
Stacey B. Griner PhD, MPH
Annalynn M. Galvin, MSN, RN
Tracey E. Barnett, PhD
Abstract
Revised U.S. guidelines for cervical cancer screening provide the option of primary human
papillomavirus (HPV) testing, Pap testing, or co-testing. Primary HPV testing has not yet been an
option for American women, and women may be reluctant to change screening methods. The
purpose of this study was to assess correlates of women’s preferences for primary HPV testing
decision-making (self, provider, or shared) for cervical cancer screening. Women, aged 30-65,
completed an online survey in June of 2018 (n = 812). The outcome variable was preference for
decision-making for an HPV test instead of a Pap test on a scale of, healthcare provider, me, or
shared. Predictor variables included testing attitudes, social norms, information seeking, previous
screening, and socio-demographics. Women who disagreed that people important to them think
that they should get the HPV test instead of a Pap test, who were not willing to receive an HPV
test instead of a Pap test, and who did not receive HPV vaccinations were less likely to include a
provider in their decision-making. In contrast, women who were not up-to-date with their cervical
cancer screenings, who had some college or technical level education, or who were over 50 years
of age were more likely to prefer to have a healthcare provider included in their decision-making
process. While some variation was discovered, women mostly preferred a shared decision or
personal decision for HPV testing. Resources to facilitate the decision-making process about this
new option for cervical cancer screening are needed.
*Corresponding author can be reached at: Erika.Thompson@unthsc.edu
Introduction
Human papillomavirus (HPV) causes
virtually all cases of cervical cancer
(Walboomers et al., 1999). While cervical
cancer was previously the leading cause of
cancer death among women in the United
States (U.S.), screening has reduced these
rates dramatically. In 2017, 12,831 cervical
cancer cases were reported in the U.S., and
4,207 deaths due to cervical cancer occurred;
rates were higher among black and Hispanic
women compared to white women (U.S.
Cancer Statistics Working Group, 2020). The
majority of cervical cancer cases are
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attributed to lack of screening among women
by failing to identify pre-cancers before they
develop into cervical cancer (Melnikow et
al., 2018), and current cervical cancer
screening data indicate 81% of women in the
U.S. are up-to-date on screening (National
Cancer Institute, 2020). In order to eliminate
cervical cancer in the U.S., increasing
screening to 90% can speed up this goal
(Burger et al., 2020).
In 2018, the U.S. Preventive Services
Task Force revised the recommendations for
cervical cancer screening to provide the
option of primary HPV testing every five
years among women 30-65 years of age.
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Women in this age group also have the option
of Pap testing every three years or co-testing
(Pap testing plus HPV testing) every five
years. The rationale for providing the option
of primary HPV testing is due to the
improved sensitivity of the test and improved
cost-effectiveness due to wider screening
intervals (Curry et al., 2018).
While studies indicate many U.S. women
report primary HPV testing as acceptable,
women may find HPV testing less acceptable
when they have negative attitudes about
delayed screening intervals, are married, and
have negative emotions related to HPV
testing (Tatar et al., 2018). Similarly, some
countries have faced resistance when cervical
cancer screening programs transitioned
completely to primary HPV testing rather
than a Pap test (Chrysostomou et al., 2018).
This may be attributed to confusion regarding
what a Pap test actually screens (Daley et al.,
2010; Perrin et al., 2006). Additionally,
healthcare providers may be unprepared for
this guideline transition, which may be
attributed to concerns about interval length
for screening, concerns about patients’
reactions to HPV testing being a sexually
transmitted infection test, and variation in
following guidelines by clinics (Head et al.,
2020; Tatar et al., 2019).
According to the U.S. Community Guide,
one-on-one counseling is recommended for
healthcare providers and patients to promote
cervical cancer screening (Community
Preventive Services Task Force, 2012). In
order to promote cervical cancer screening in
the midst of this guideline transition with the
option of HPV-only testing, there is a need to
explore the screening decision-making role
preferences of women with different health
histories, sociodemographic backgrounds,
attitudes, and knowledge levels. This study
explored women’s preferences for decisionmaking for HPV testing instead of Pap
testing; specifically, making the decision
themselves, a shared decision with their
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provider, or relying on a provider to make the
decision. Findings from this study can inform
counseling strategies healthcare providers
utilize with their patients in order to promote
cervical cancer screening.
Methods
Study Sample
The target population for this study was
women who are eligible for receiving HPV
testing according to the recent guideline’s
recommendations: 30-65 years of age,
without the history of hysterectomy. The
recruitment of participants was conducted
through the Qualtrics Online Panel, and
African American and Hispanic women were
oversampled due to the higher burden of
cervical cancer among these populations
(U.S. Cancer Statistics Working Group,
2020). Research panel members were invited
to participate in the survey. Eligible women
participated in the survey after providing
informed consent presented at the beginning
of the survey. Data were collected in June of
2018 with a sample size of 812 participants.
The study was approved with an exempt
status by the North Texas Regional
Institutional Review Board.
Measures
The outcome variable, using a scaled
measure, assessed the decision-making role
preference of the participant and asked,
“Whether I would have an HPV test instead
of a Pap test would be entirely up to...” The
participant then had the option of choosing a
number on a sliding scale ranging from 1 to
100 with lower values indicating independent
decision-making, moderate range values
indicating a preference for shared decision
making with the provider, and higher values
indicating a preference for the healthcare
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provider to make the decision. This variable
was used as a continuous variable.
The
predictor
variables
included
sociodemographic factors and variables that
have previously been found to have an
association with the cervical cancer screening
decision-making preferences of an individual
(Tatar et al., 2018). Sociodemographic
variables included age (30-50 years, ≥ 50
years), highest educational level attained
(high school or less, some college/technical,
4 years of college or higher), race (white,
black, others), and ethnicity (non-Hispanic,
Hispanic).
HPV knowledge was assessed by utilizing
a validated 16-item knowledge scale by Perez
and colleagues (Perez et al., 2016). In
response to 16 HPV-related statements,
participants responded “True,” “False,” or
“Don’t Know.” Correct responses were
assigned a point, and all correct points were
summed and averaged, with higher scores
indicating increased HPV knowledge. The
Cronbach’s alpha for this sample was 0.89.
For HPV testing awareness, the study asked,
“Have you ever heard of HPV testing?”
(“Yes,” “No,” and “Don’t know”).
Participants who responded “No” and “Don’t
know” were recoded into a “No” category.
Ease of finding and understanding cervical
cancer information used questions from the
European
Health
Literacy
Survey
Questionnaire
(HLS-EU-Q),
adapted
specifically for cervical cancer information
(Sørensen et al., 2013). When asked “How
easy is it for you to find information on
cervical cancer screening?” and “How easy is
it for you to understand information on
cervical cancer screening?”, response options
included very easy, easy, somewhat easy, and
not easy. Due to response distribution,
responses of somewhat easy and not easy
were collapsed into a single category.
HPV testing attitudes, subjective norms,
and provider recommendation were also
assessed. An HPV testing attitude scale
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adapted from Ogilvie and colleges (Ogilvie et
al., 2013) was assessed: “Having an HPV test
to screen for cervical cancer every 5 years
and after age 30 instead of a Pap smear every
3 years would be: accurate/safe/protect my
health/acceptable.”
Response
options
ranging from strongly agree to strongly
disagree were aggregated to produce a sum
score (α = 0.946). Ogilvie and colleagues’
(Ogilvie et al., 2013) subjective norms
question was also adapted: “If national
guidelines recommended having an HPV test
to screen for cervical cancer instead of a Pap
smear, most people who are important to me
would think I should/expect me to have an
HPV test instead of a Pap smear.” Due to the
bimodal distribution of the variable, the
seven responses were recoded into three
categories: “Agree” (“Strongly agree,”
“Agree,” and “Somewhat agree”); “Neither
agree nor disagree”; and “Disagree”
(“Strongly disagree,” “Disagree,” and
“Somewhat disagree”). Whether the
participant agreed to have HPV testing
instead of Pap testing based on a healthcare
provider’s recommendation was assessed,
with responses of “Yes,” “No,” or “Don’t
know.” (Saraiya et al., 2018) “No” and
“Don’t know” responses were re-coded as
“No.”
Relevant health history (i.e., screening upto-date, HPV vaccination, and non-HPV
sexually transmitted infection diagnosis
history) was also assessed. Up-to-date with
2018 cervical cancer screening guidelines
status was determined with two questions:
“How long ago did you have your most recent
Pap test?” (from the Health Information
National Trends Survey), and “An HPV test
is sometimes given with the Pap test for
cervical cancer screening. Did you have an
HPV test with your most recent Pap?” (from
the 2014 National Health Interview Survey).
If the participant reported having a Pap test
within the last three years or an HPV test with
their last Pap test within 5 years, the
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participant was up-to-date. Otherwise, the
participant was not up-to-date. History of any
HPV vaccination was assessed, with
responses of “Yes,” “No,” and “Don’t
know.” History of a sexually transmitted
infection diagnosis other than HPV was also
assessed with responses of “Yes,” “No,” and
“Don’t know,” recoding “No” and “Don’t
know” responses into one category.
Data Analysis
We conducted the univariate and bivariate
analysis for the continuous outcome variable
assessing the shared decision-making
preference. Multiple linear regression was
used to identify the predictor variables
independently associated with decisionmaking preference. The multiple linear

regression model was significant and
accounted for 8.7% of the variance with F(20,
791) = 3.79, p < 0.01. The assumptions for
the model were tested and all the assumptions
were met. All the variables that are
considered essential for health-related
decision-making were entered in the model
together. Adjusted regression coefficients
and p-values were reported. The analysis was
conducted using SAS 9.4 software.
Results
Among the 812 women surveyed, 63%
were between 30 to 50 years old, 68% of the
women were white, 23% were black, and 9%
were of other race(s); 19% were Hispanic
(Table 1).

Table 1
Demographic and Health Behavior Characteristics of Sample (n = 812)
Variable
Decision-Making (mean (SD))a
Attitude Towards HPV Test (mean (SD))b
HPV Knowledge Score (mean (SD))c
People Important to Me Think I Should Have HPV Test Instead of Pap
Test
Agree
Neither Agree nor Disagree
Disagree
Up-to-Date with Cervical Cancer Screening
Up-to-Date
Not Up-to-Date
Agree to Have HPV Test Instead of Pap Test on Doctor's
Recommendation
Yes
No
Ease of Finding Cervical Cancer Screening Information
Very Easy
Easy
Somewhat/Not Easy
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n (%)
44.67 (32.31)
20.86 (5.49)
8.10 (4.58)
445 (54.80)
303 (37.32)
64 (7.88)
580 (71.43)
232 (28.57)
505 (62.19)
307 (37.81)
341 (42.00)
289 (35.59)
182 (22.41)
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Table 1 (continued)
Demographic and Health Behavior Characteristics of Sample (n = 812)
Variable
n (%)
Ease of Understanding Cervical Cancer Screening Information
Very Easy
303 (37.32)
Easy
285 (35.10)
Somewhat/Not Easy
224 (27.59)
Education
Less than High School/High School
270 (33.25)
Some College/Technical
296 (36.45)
College
246 (30.30)
Age
< 50 years
514 (63.30)
≥ 50 years
298 (36.70)
Race
White
553 (68.10)
Black
187 (23.03)
Other Race, including Bi/Multiracial
72 (8.87)
Ethnicity
Non-Hispanic
661 (81.40)
Hispanic
151 (18.60)
Heard of HPV Testing
Yes
507 (62.44)
No/Don't Know
305 (37.56)
Received HPV Vaccination
Yes
100 (12.32)
No
592 (72.91)
Don't Know
120 (14.78)
Ever Had a Sexually Transmitted Infection Other than HPV
Yes
135 (16.63)
No/Don't Know
677 (83.37)
Note. aDecision-making scale: 1 to 100; bAttitudes scale: 4 to 28; cKnowledge scale: 0 to 16
Most of the women had some college or
technical school education (36%). The mean
decision-making score was 44.7 (SD = 32.3),
indicating that more women preferred shared
decision-making with their healthcare
provider (Figure 1). Nearly two-thirds (62%)
of the women had heard of HPV testing
before, and only 12% of the women had ever
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received HPV vaccination. The mean score
for attitude towards HPV testing was 20.9
(SD = 5.5), with a range between 4 and 28,
suggesting that more women agreed that
HPV testing is safe, accurate, acceptable, and
protected their health. The mean HPV
knowledge score was 8.1 (SD = 4.6) out of
16, which shows that women had relatively
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low knowledge regarding HPV. Most women
agreed that people important to them think
they should get an HPV test instead of a Pap
test (55%), and they would be willing to get
an HPV test instead of a Pap test on their
doctor’s recommendation (62%). More than
two-thirds (71%) of the women were up-todate with their cervical cancer screening.
Most of the women considered it was very
easy or easy to find (78%) and understand
(72%) cervical cancer screening information.
Table 2 presents the coefficients from the
adjusted linear regression model. After
controlling for other variables, women who
disagreed with the statement that people who
are important to them think that they should
get HPV test instead of Pap test were less
likely to prefer their provider to decide for
them (b = -11.03). Women who did not agree
to receiving an HPV test instead of a Pap test
were more likely to make the decision
independently (b = -7.50). Women who had
some college or technical level education (b
= -6.18) or who were over 50 years old (b = 5.13) were more likely to make the decision
independently. Women who did not receive

HPV vaccination were less likely to include
healthcare provider in their decision-making
(b = -8.70). Women who were not up-to-date
with cervical cancer screening were more
likely to prefer their provider to make a
decision (b = 5.27). Furthermore, women
from non-white or non-black identified races
were more likely to prefer a healthcare
provider to be involved in decision-making
(b = 10.67).
Discussion
With the recent option of primary HPV
testing as a mode for cervical cancer
screening in the United States, understanding
women’s preferences for deciding on primary
HPV testing can inform strategies that
increase screening for the elimination of
cervical cancer. Perhaps most important, this
study found women preferred an individual
decision-making approach and that decisionmaking preferences were influenced by
sociodemographic and past health behavior
variables.

Figure 1. Distribution of the decision-making score for HPV testing (n = 812).
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Table 2
Adjusted Linear Regression Model of HPV Testing Decision-making Preference among
Women (n = 812)

Variable
Attitude Towards HPV Test
HPV Knowledge Score
People Important to Me Think I Should Have HPV Test
Instead of Pap Test
Agree
Neither Agree nor Disagree
Disagree
Up-to-Date with Cervical Cancer Screening
Up-to-Date
Not Up-to Date
Agree to Have HPV Test Instead of Pap Test on Doctor's
Recommendation
Yes
No
Ease of Finding Cervical Cancer Screening Information
Very Easy
Easy
Somewhat/Not Easy
Ease of Understanding Cervical Cancer Screening
Information
Very Easy
Easy
Somewhat/Not Easy
Education
Less than High School/High School
Some College/Technical
College
Age
< 50 years
≥ 50 years
Race
White
Black
Other Race, including Bi/Multiracial

Published by New Prairie Press, 2021

Adjusted Linear
Regression
Coefficientsa (SE)
0.07 (0.24)

p-value
0.75

Ref
-1.81 (2.62)
-11.03 (4.65)

0.49
0.02

Ref
5.27 (2.59)

0.04

Ref
-7.50 (2.57)

<0.01

3.19 (3.89)
2.04 (3.51)
Ref

0.41
0.56

1.29 (3.67)
0.67 (3.28)
Ref

0.73
0.84

Ref
-6.18 (2.72)
-1.55 (2.94)

0.02
0.60

Ref
-5.13 (2.43)

0.04

Ref
3.68 (2.78)
10.67 (4.09)

0.19
0.01
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Table 2
Adjusted Linear Regression Model of HPV Testing Decision-making Preference among
Women (n = 812)

Variable
Ethnicity
Non-Hispanic
Hispanic
Heard of HPV Testing
Yes
No/Don't Know
Received HPV Vaccination
Yes
No
Don't Know
Ever Had a Sexually Transmitted Infection Other than
HPV
Yes
No/Don't Know
Note. aunstandardized
Below, we discuss the findings of this study
and highlight implications for clinical
practice and future work.
The majority of women in this study
indicated that they strongly preferred an
individual or shared decision-making
approach, with the lowest being a preference
for provider-only decision. These findings
are consistent with a shared decision-making
approach, which “rests on accepting that
individual self-determination is a desirable
goal and that clinicians need to support
patients to achieve this goal” (Elwyn et al.,
2012). As the United States considers moving
toward HPV testing for cervical cancer
screening, incorporating shared decisionmaking strategies into the one-on-one
counseling of patients considering HPV-only
testing is imperative.
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Adjusted Linear
Regression
Coefficientsa (SE)

p-value

Ref
-2.96 (3.10)

0.33

Ref
3.39 (2.70)

0.21

Ref
-8.70 (3.56)
-1.47 (4.48)

0.01
0.74

Ref
1.41 (3.05)

0.64

To incorporate shared decision-making
for HPV testing, clinicians should consider
providing information to women regarding
HPV testing and presenting the options,
intervals, risks, and benefits, so women can
make an informed decision for their needs.
Additionally, it has been noted that
guidelines and recommendations for
screening do not often address women’s
preferences or values and do not provide
specific recommendations for providers to
discuss (Sawaya & Kuppermann, 2015).
Studies on cervical cancer screening have
noted that women wanted to be
knowledgeable enough to weigh their options
and choose an option for them based on their
values, but women also wanted input from
their providers (Wood et al., 2018).
Healthcare providers report taking paternal-
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istic approaches when discussing options, as
they wanted women to have the autonomy to
make decisions but remain within the context
of the evidence-based recommendations
(Wood et al., 2018). In these situations,
women may find it difficult to act on their
preferred decision if it does not align with
their provider’s preferred decision, reducing
the amount of autonomy women are able to
exert over their screening (Adams et al.,
2012). Furthermore, when discussing cancer
screening decisions with providers, patients
report that these discussions mostly focused
on the pros of screening and less often
included a focus on the potential cons
(Hoffman et al., 2010). Instead, it is
imperative that any shared decision-making
approach reflects the idea that the provider’s
role is to “be a navigator, not a pilot” by
ensuring that patients are using relevant and
accurate information in their decisionmaking and that they understand the
ramifications of their choice (McNutt, 2004).
Exploring providers’ perceptions of shared
decision-making for HPV testing may shed
light on empowering communication
approaches to utilize during these
discussions, as people who are involved in
decision-making regarding their health report
better health outcomes (Hibbard & Greene,
2013; Hoffmann et al., 2014). Further
research is needed to determine whether
these findings hold true with HPV testing.
Just 12% of this sample reported ever
receiving the HPV vaccine, and women who
had not been vaccinated for HPV were more
likely to prefer making a personal decision
for HPV testing, compared to those who were
vaccinated. Almost half of providers in one
study said that patient HPV vaccine status
influenced their cervical cancer screening
practices (Cooper & Saraiya, 2017). Receipt
of the HPV vaccine has been associated with
higher rates of screening adherence (Chao et
al., 2017).
In the HPV testing
recommendation from the U.S. Preventive
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Services Task Force, many screening
approaches and intervals are presented
(United States Preventive Services Task
Force, 2018). Given these options, the
Community Preventive Services Task Force
recommends the use of patient-provider
communication with a goal of “informing,
encouraging, and motivating” patients to
seek cervical cancer screening (Community
Preventive Services Task Force, 2020),
strengthening the argument to consider a
shared decision-making approach to HPV
testing. Specifically, women who have not
received the vaccine may mistrust providers
and the healthcare system and have difficulty
talking to their providers (Kolar et al., 2015),
therefore opting to prefer an individual
decision about screening. Tailored materials
and counseling strategies addressing this
mistrust may improve patient-provider
communication and facilitate shared
decision-making for cervical cancer
screening, as women were more confident in
their decision-making without provider
influence if they were informed (Wood et al.,
2018).
Women who attended some college,
compared to women with high school or less
education, were more likely to prefer to make
the decision themselves about HPV
screening. There were no differences,
however, between women who completed
college and those with a high school or less
education for decision-making preferences.
Similarly, previous studies have found
variation in HPV and cervical cancer
knowledge and HPV testing acceptability
based of educational attainment (Thompson
et al., 2018). In contrast, women who are not
white or black were more likely to prefer that
a healthcare provider be involved in the
decision-making; however, disentangling the
heterogeneity within the “other” racial group
may identify different patterns among
specific groups of women. Future studies
should explore the socio-cultural differences
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in cervical cancer screening decision-making
among women and how these differences
may inform prevention programming.
Findings must be considered in light of a
few limitations. As a cross-sectional study,
generalizations regarding the temporality of
associations cannot be determined based on
this study alone. Additionally, since the data
were collected via Qualtrics Online Panels,
generalizability is limited. U.S. participants
in online survey panel studies have been
shown to be less diverse compared to studies
with clinical samples, based on racial and
ethnic disparities in language, Internet
access, and frequency of survey participation
(Grov et al., 2016; Ibarra et al., 2018).
Utilizing quota sampling to account for more
black and Hispanic women partially
addressed this limitation, but women who did
not speak English were excluded from the
sample. Moreover, data were reported via
self-report, which may result in less
reliability in reporting screening behaviors
when compared to utilizing medical record
data (Anderson et al., 2019). Providing
educational content within the survey
regarding guideline recommendations and
explanations of HPV tests and Pap tests
mitigated some recall bias. Finally, the
question for assessing preference for a
decision was on a large, zero-to-100 scale and
had significant variability. Future studies
may consider utilizing a fixed response
option for this type of question.
Implications for Health Behavior Theory
This
study
examined
women’s
preferences for an individual, shared, or
provider-based decision for HPV testing
compared to Pap testing. With this new
transition in recommended guidelines for
cervical cancer screening, recognizing
women’s preferences is needed for patientcentered programming to improve cervical
cancer screening rates. Ultimately, im-
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proving cervical cancer screening, particularly among under-screened women, has
the potential to contribute to the overall goal
of eliminating cervical cancer in the United
States.
In order to successfully implement
primary HPV testing as a mode of cervical
cancer screening, the preferences of women
need to be recognized for shared decisionmaking. Variation in preferences exist for
women spanning from individual decision, a
shared decision, and a provider –based
decision. Providers should incorporate
women’s preferences when providing oneon-one discussions to promote cervical
cancer screening.
Discussion Question
What are strategies to involve women in the
decision-making process for transitioning to
HPV testing instead of Pap testing for
cervical cancer screening?
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